NCT00063414View on ClinicalTrials.gov

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 20, 2002

Primary Completion Date

March 24, 2005

Study Completion Date

March 24, 2005

Conditions
Ulcerative Colitis
Interventions
DRUG

Alicaforsen

Trial Locations (1)

Unknown

Chicago

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY